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Abstract 
Background: Amikacin inhale (BAY41-6551), a unique drug—device combination of a specially formulated drug 
solution and a pulmonary drug delivery system device (AMK-I) is currently under phase III study as an adjunctive 
therapy to IV antibiotics for the treatment of Gram-negative pneumonia in mechanically ventilated patients. While 
the epidemiology of nosocomial pneumonia is predominated by Gram-negative pathogens such as Pseudomonas 
aeruginosa and the Enterobacteriaceae, Staphylococcus aureus is increasingly recognized as a pathogen of concern for 
these pulmonary based infections. Since the aminoglycosides are historically quite active against S. aureus the use of 
adjunctive AMK-I may enhance bacterial eradication. Herein, we aimed to characterize the in vitro pharmacodynamic 
(PD) profile of human-simulated ELF exposures of AMK-I against both methicillin-sensitive (MSSA) and -resistant 
(MRSA) S. aureus.
Methods: An in vitro model was used to simulate the resultant ELF pharmacokinetic profile of amikacin after the 
administration of AMK-I 400 mg q12h. The antibacterial activity of this regimen was tested against 7 S. aureus isolates 
that display MIC profiles encountered clinically (4 MRSA; MIC range 4–64, 3 MSSA; MIC range 8–16 mg/L). Experiments 
were conducted over 24 h and samples were taken throughout this period to assess the bacterial density in both 
control and treatments.
Results: The mean ± SD inoculum 0 h bacterial density was 6.4 ± 0.09 which increased to 8.6 ± 0.19 log10 CFU/
mL in the control models by the end of 24 h experiments. Simulated ELF concentrations of AMK-I resulted in a rapid, 
5 log10 declined in CFU over the initial 12 h for all MRSA and MSSA isolates. After 12 h, all bacterial counts remained 
below the limit of detection (LOD, 1.7 log10 CFU/mL) and no regrowth was evident at the end of the study.
Conclusion: AMK-I produced an ELF exposure profile that was rapidly bactericidal against S. aureus displaying typi-
cal MICs to amikacin irrespective of their phenotypic profile to methicillin. While the Gram-negative organisms are 
the target pathogens for AMK-I in the ongoing clinical trials, these data suggest that this adjunctive regimen may 
also have the potential to eradicate both MSSA and MRSA from lower airway which needs to be further evaluated in 
randomized-controlled clinical trials.
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Background
It has been long recognized that amikacin displayed 
potent activity against Staphylococcus aureus including 
methicillin-resistant (MRSA); however, due to availability 
of other less toxic agents, amikacin has been historically 
reserved for Gram-negative pathogens [1, 2]. Although 
Gram-negative organisms are prevalent in ventila-
tor associated pneumonia (VAP), S. aureus phenotypes 
(MSSA and MRSA) are increasingly abundant and may 
account for up to 28% of infecting pathogens [3].
While parenteral amikacin has been useful for the 
treatment of variety of infections, including VAP, the 
emergence of multidrug resistant pathogens and the per-
sistent potency of amikacin have re-invigorated interest 
in the compound. As a result of the challenge of deliver-
ing sufficiently high concentrations of aminoglycosides 
to the lungs for the treatment of VAP, a novel inhaled 
amikacin formulation was developed. Amikacin inhale 
(BAY41-6551) is a drug-devise combination currently 
being assessed for the management of Gram-negative 
pneumonia in the intubated patients. The pulmonary 
drug delivery system (PDDS) nebulizer can be attached 
to the standard mechanical ventilation equipment or to 
portable handheld unit delivering approximately 50–70% 
of the nominal dose to the lower airways [4]. Previously 
we have shown that the resultant high local bronchopul-
monary exposure profile of amikacin achieved with this 
administration technique was able to eradicate Entero-
bacteriaceae and Pseudomonas aeruginosa despite ele-
vated MICs as currently defined by clinical laboratory 
criteria [5]. In addition to the high achievable amikacin 
ELF concentrations after inhalation another attribute of 
this pulmonary delivery technique is the low systemic 
exposure [6].
As a result of the prevalence of polymicrobial infec-
tions with S. aureus in VAP, we sought to investigate the 
anti-staphylococcal activity of humanized ELF exposure 
of amikacin inhale delivered via PDDS.
Methods
Due to the limited availability of commercially pre-
pared amikacin intravenous solution, pharmaceutical 
grade amikacin powder (Medisca, Plattsburg, NY, USA) 
was acquired from our institutions’ pharmacy for use in 
in vitro pharmacodynamic model. Prior to the conduct of 
the pharmacodynamic studies, an initial run was under-
taken in duplicate to confirm the equal biological potency 
of amikacin solution when prepared from the powder 
and commercially available vials. Standard analytical 
grade amikacin was purchased from Sigma-Aldrich (St. 
Louis, MO, USA) for MIC testing as per Clinical Labo-
ratory Standards Institute (CLSI) recommendations. 
MIC studies were performed in triplicate by broth micro 
dilution per CLSI [7] methodology and the modal value 
reported. S. aureus isolates (n = 24) from a previous sur-
veillance study [8] were screened and 7 were included (3 
MSSA; MIC 8–16 mg/L and 4 MRSA; MIC 4–64 mg/L) 
to cover 99% of MIC range encountered clinically [9].
The mean steady-state ELF concentrations of amikacin 
400 mg q12h delivered via PDDS [10], were simulated in 
the in  vitro pharmacodynamic model with target peak 
and trough concentration of 5250 and 507 mg/L, respec-
tively, resulting in an area under the curve (AUC0−12) of 
17,940 mg h/L. A simulated dynamic in vitro model was 
used for all experiments as previously described [11]. 
Briefly, each experiment consisted of two treatment mod-
els and one growth control model running simultane-
ously for each isolate. For optimal temperature control, 
the models were placed in a 37  °C water bath operated 
by temperature and circulation controller (PolyScience, 
Niles, IL, USA).
A starting (0  h) inoculum in each model was targeted 
to be  ~106  CFU/mL. Each model was filled with cation 
adjusted Mueller–Hinton Broth (CAMHB) (Becton, Dick-
inson and Company, Sparks, MD) and inoculated 30  min 
before starting dosing, then amikacin was administered at 
simulated exposures (0  h). A peristaltic pump (Masterflex 
L/S Model 7524-40; Cole-Parmer Instrument Company, 
USA) was utilized to simulate half-life in ELF. From a phar-
macokinetic standpoint, the model consists of 300 mL glass 
containers representing the volume of distribution, the drug 
is bolused to achieve the desired peak and pumps deliver 
fresh CAMHB to the glass containers representing drug 
clearance to mimic calculated half-life. From a pharmacody-
namics standpoint, samples were obtained from each model 
at pre-defined time points to assess changes in bacterial 
density relative to drug-free control model. Aliquots of each 
diluted sample were plated on Trypticase soy agar plates 
with 5% sheep blood (BAP, BD Biosciences, Sparks, MD) 
and incubated at 37 °C for 16–20 h for quantitative culture. 
To eliminate the interference of antibiotic carry over, 2 safe-
guards were applied; samples were serially diluted and if any 
area of inhibited growth had been observed on the plate, it 
was excluded from the study. As a measure of the antibacte-
rial activity over the 24 h, log10 CFU/mL of test isolate was 
plotted versus time. The lower limit of detection for bacte-
rial density was 1.7 log10 CFU/mL. To ensure target expo-
sures in the model, amikacin concentrations were sampled 
at pre-defined time points, and assayed by Quest Diagnos-
tics (Chantilly, VA, USA) using a commercially available kit 
(Siemens Healthcare Diagnostics, Deerfield, IL, USA).
Results
A comparison of the amikacin solutions prepared 
from the powder and commercially available vials 
revealed a similar time-killing profile thus proving the 
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interchangeability of the amikacin sources. As a result of 
the availability of sufficient quantities of amikacin pow-
der, this preparation was utilized in all in vitro modeling 
experimentation.
The observed pharmacokinetic parameters 
(mean  ±  SD) for amikacin derived from the 14 indi-
vidual experiments (peak 4282  ±  743  mg/L, trough 
498 ± 154 mg/L, AUC0−12 16512 ± 2229 mg h/L) were 
similar to the targeted values (Fig. 1). The average bacte-
rial density of the starting inoculum was 6.4 ± 0.09 log10 
CFU/mL, increasing to 8.6  ±  0.19 4 log10 CFU/mL in 
control models by the end of the 24 h period. Figures 2 
and 3 show the mean bacterial densities over the 24  h 
exposure period for MSSA and MRSA isolates respec-
tively. Amikacin simulated concentration achieved maxi-
mal killing effect within 12 h, and sustained bactericidal 
activity at the lower limit of detection (1.7 log10 CFU/
mL) over 24 h. While the overall extent of kill was simi-
lar for both MSSA and MRSA isolates, an initially faster 
rate of kill was observed for some isolates with MICs of 
4–8 mg/L.
Discussion
The current study demonstrates, using an in vitro model, 
that pulmonary amikacin exposures achieved by inhala-
tion via PDDS are highly active against S. aureus isolates 
irrespective of methicillin resistance phenotype, up to a 
MIC of 64 mg/L which encompasses 99% of clinical iso-
lates [9].
From a pharmacodynamic standpoint, the initial pro-
nounced killing and sustained effect noted, fits the ami-
noglycosides’ well established characteristics of rapid 
initial binding to the bacterial cell and prolonged persis-
tent bactericidal activity [12]. Moreover, our observed 
killing profile is consistent with the established phar-
macodynamic targets of the aminoglycosides as our 
calculated parameters of AUC0−12/MIC and peak/MIC 
for these organisms were well above that required for 
antibacterial efficacy [13].
Despite the lack of clinical data with amikacin, stud-
ies have demonstrated the utility of other aminoglyco-
sides against infections caused by S. aureus as in case 
of gentamicin that successfully treated several infection 
sites [14]. Recently arbekacin was found to be a safe and 
effective alternative to vancomycin to treat S. aureus 
infections [15]. These data prove the efficacy of amino-
glycosides against S. aureus but monotherapy is not a 
commonplace.
One potential limitation of our study is the absence of 
surfactants in the model. While it has been shown that 
lung surfactant affects the activity of antibiotics due to 
drug binding to surfactant proteins or phospholipids, 
the aminoglycosides are lowly protein bound and poorly 
charged agents and thus are not expected to bind to this 
biological matrix. Moreover, since inhaled amikacin is 
being investigated in clinical trials, we aimed to dem-
onstrate the microbiologic activity resulting from the 
achievable ELF concentrations of the compound against 
S. aureus to provide insights regarding its antibacterial 
properties in the lower airway [16–18].
An additional limitation of the current study is the 
use of a PK model that was derived by conducting 
simulation with PK data of mechanically ventilated 
patients (n  =  28) with lower respiratory tract infec-
tions who were administered amikacin through PDDS 
[6]. Although the simulated model was not validated in 
a clinical study, we believe that the patient population 
and thus the derived amikacin ELF profile is sufficiently 
robust to support its use in our preclinical evaluation 
against S. aureus. Nonetheless, the results of preclinical Fig. 1 Expected and observed amikacin epithelial lining fluid profiles
Fig. 2 Mean bacterial density of MSSA isolates tested (amikacin MIC, 
mg/L) in simulated epithelial lining fluid concentrations of inhaled 
amikacin
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studies should be interpreted with caution and sub-
stantiated by clinical evidence before the intervention 
of interest is integrated into the management of the 
infected patients.
Conclusions
While the notion of amikacin antistaphylococcal activ-
ity is recognized, the current study points out that the 
exquisitely high amikacin concentrations achieved locally 
in the lungs through inhalation coupled with the com-
pound’s inherent bactericidal activity provide extensive 
killing of S. aureus inclusive of those isolates with MICs 
at the top end of the distribution (i.e., MIC 64  mg/L). 
Recognizing that clinical trial data are required to define 
the role of amikacin inhale for the management of VAP 
due to S. aureus, the current data set provides new 
insights into the potential utility of this novel therapeu-
tic approach for this increasingly prevalent pathogen in 
the setting of nosocomially acquired bronchopulmonary 
infections.
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